Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 7/20 | 1.00 |
| ▸ | CLK1 | P49759 | 4/20 | 1.00 |
| ▸ | MAP3K5 | Q99683 | 11/20 | 0.79 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR1E | P28566 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486166 | 0.88 | MAP3K5 (1.00) | CLK2CLK1MAP3K5HRH1HTR1A | |
| SCHEMBL3486676 | 0.83 | CLK2 (0.75) | CLK2CLK1MAP3K5HRH1HTR1A | |
| SCHEMBL3485554 | 0.83 | MAP3K5 (0.83) | CLK2CLK1MAP3K5HRH1HTR1A | |
| SCHEMBL3487230 | 0.83 | MAP3K5 (0.82) | CLK2CLK1MAP3K5HRH1HTR1A | |
| SCHEMBL3485541 | 0.83 | CLK2 (0.80) | CLK2CLK1MAP3K5HRH1HTR1A | |
| SCHEMBL3486027 | 0.83 | MAP3K5 (0.82) | CLK2CLK1MAP3K5HRH1HTR1A | |
| SCHEMBL3485455 | 0.81 | CLK1 (0.71) | CLK2CLK1MAP3K5MCHR1 | |
| SCHEMBL3486095 | 0.80 | CLK2 (0.73) | CLK2CLK1MAP3K5HRH1HTR1A | |
| Hydrochloric Acid SCHEMBL3486014 | 0.79 | CLK2 (0.72) | CLK2CLK1MAP3K5HRH1HTR1A | |
| SCHEMBL3486061 | 0.74 | MAP3K5 (0.77) | CLK2CLK1MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | IRAK1, IL1R1, IRAK2 | CLK2 2521/4885CLK1 2385/4885MAP3K5 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.